Related Experiment Video
Updated: Aug 14, 2026
Two Methods for Establishing Primary Human Endometrial Stromal Cells from Hysterectomy Specimens
Published on: May 23, 2014
2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth
Frederic Amant1, Mona Liza Lottering, Annie Joubert
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium. Frederic.Amant@uz.kuleuven.ac.be
Objectives:
The objective was to test the hypothesis that uterine sarcomatous cells are hormone-sensitive. We included 2-methoxyestradiol, an endogenous metabolite of estradiol with antiproliferative properties.
Methods:
Proliferation assays assessed the effects of estradiol, progesterone, tamoxifen, raloxifen, [D-Trp(6)]leuteinizing hormone-releasing hormone (LHRH), ICI 182,780 (faslodex or fulvestrant), and 2-methoxyestradiol on cell growth of a cell line derived from uterine carcinosarcoma, but consisting solely of mesenchymal cells (SK-UT-1). Morphological changes of SK-UT-1 cells after exposure to 2-methoxyestradiol were evaluated and fluorescence immunohistochemistry for tubulin was used to detect changes in the mitotic spindle. Flow cytometry was used to assess the influence of 2-methoxyestradiol on the SK-UT-1 cell cycle as well as the role of p53 in apoptosis.
Results:
Cell proliferation analysis revealed that SK-UT-1 cells were stimulated by progesterone, tamoxifen, and [D-Trp(6)]LHRH. Cells were insensitive to estradiol, raloxifen, and ICI 182,780. Inhibition occurred after exposure to 2-methoxyestradiol and was accompanied by a threefold increase in the G2/M population, with a concomitant decrease in the G1 population, as shown by cell cycle analysis. SK-UT-1 cells exposed to 2-methoxyestradiol showed morphological changes indicative of apoptosis. Examination of signaling pathways that mediate 2-methoxyestradiol-induced apoptosis showed p53-independent growth inhibition. The inhibition of SK-UT-1 cell growth by arresting the cells during G2/M progression could be attributed to interference with the microtubule system, as determined by fluorescence immunohistochemistry.
Conclusions:
The stimulatory effect of progesterone, tamoxifen, and [D-Trp(6)]LHRH suggests that uterine sarcomatous cells are hormone-sensitive. Our finding that 2-methoxyestradiol-mediated growth inhibition of uterine sarcomatous cells occurred in a p53-independent manner may have considerable clinical significance. The inadequate armature against uterine sarcomas and the limited toxicity of 2-methoxyestradiol may render these observations especially important.
Insights
Uterine sarcomatous cells show hormone sensitivity, responding to progesterone, tamoxifen, and LHRH. 2-methoxyestradiol inhibits growth via microtubule disruption, independent of p53, offering potential therapeutic avenues.
Area of Science:
- Gynecologic Oncology
- Endocrinology
- Cell Biology
Background:
- Uterine sarcomas are rare malignancies with limited treatment options.
- The hormone sensitivity of uterine sarcomatous cells remains incompletely understood.
- 2-methoxyestradiol, an endogenous estradiol metabolite, exhibits antiproliferative effects.
Purpose of the Study:
- To investigate the hormone sensitivity of uterine sarcomatous cells.
- To evaluate the effects of various hormones and 2-methoxyestradiol on uterine sarcoma cell growth.
- To elucidate the mechanism of 2-methoxyestradiol-induced cell cycle arrest and apoptosis.
Main Methods:
- Proliferation assays were performed on the SK-UT-1 uterine carcinosarcoma cell line.
- Cells were exposed to estradiol, progesterone, tamoxifen, raloxifene, [D-Trp(6)]LHRH, ICI 182,780, and 2-methoxyestradiol.
- Cell cycle analysis, morphological evaluation, and fluorescence immunohistochemistry for tubulin and p53 were utilized.
Main Results:
- SK-UT-1 cells demonstrated sensitivity to progesterone, tamoxifen, and [D-Trp(6)]LHRH.
- Estradiol, raloxifene, and ICI 182,780 did not affect cell proliferation.
- 2-methoxyestradiol inhibited cell growth, inducing G2/M phase arrest and apoptosis through microtubule interference, independent of p53.
Conclusions:
- Uterine sarcomatous cells exhibit sensitivity to specific hormones, suggesting potential for endocrine-based therapies.
- 2-methoxyestradiol demonstrates significant antiproliferative activity against uterine sarcoma cells via a p53-independent pathway.
- The findings highlight 2-methoxyestradiol as a promising agent for uterine sarcoma treatment due to its efficacy and low toxicity.
